Greenwich LifeSciences, Inc. Share Price & Technical Analysis
GLSI · $26.90 (-1.14%)
Healthcare / Biotechnology
$26.90
-1.14%
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also dev…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
17% return in May, 6% avg return in past 3 year May month.
43% return in 2026, 47% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 41% | -5% | -10% | -1% | 17% | – | – | – | – | – | – | – | 43% |
| 25 | 11% | -4% | -21% | 6% | -1% | -8% | 20% | 6% | -15% | -8% | -5% | 147% | 127% |
| 24 | -19% | 40% | 63% | -39% | 20% | 15% | -6% | -12% | 4% | -7% | 5% | -22% | 41% |
| 23 | 25% | -22% | -11% | -24% | -1% | -15% | -3% | -1% | -3% | -3% | 41% | -10% | -27% |
| 22 | -25% | 3% | 1% | -40% | -35% | 9% | -4% | 20% | -2% | -1% | 54% | 5% | -15% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$332.51M
P/E ratio
—
52W high
$34.10
52W low
$7.78
Volume
43,032
Beta
1.39
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Greenwich LifeSciences, Inc. share price today?
- Greenwich LifeSciences, Inc. (GLSI) last traded around $26.90 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GLSI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GLSI. Download the app for real-time alerts.
- How can I analyze Greenwich LifeSciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.